Hepatocellular carcinoma (HCC) is among the leading causes of cancer-related deaths worldwide due to lack of effective diagnosis at early stages and limited comprehension of its pathogenesis, thus limiting the development of effective treatments.
PRMT1 is a key enzyme that catalyzes asymmetric dimethylation of arginine residues and overexpressed in various cancers and inflammatory diseases. While current PRMT1 inhibitors lack specificity and effectiveness, targeted degradation of PRMT1 offers a potential strategy to treat PRMT1-driven conditions and explore its nonenzymatic roles.
Silexion Therapeutics Corp. has released preclinical data demonstrating the efficacy of its next-generation RNA interference (RNAi) therapeutic candidate, SIL-204, against human pancreatic, colorectal and lung cancer cell lines.
Targeting CDC-like kinases 2 and 3 (CLK2 and CLK3) has emerged as an effective therapeutic strategy in cancer treatment, with several compounds currently in clinical development.
Glycoengineering specialist Glycoera AG is preparing to take its extracellular protein degrader constructs into the clinic in the treatment of autoimmune diseases, after closing a $130 million series B.
RSS
